Work

Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Year: 2025

Type: supplementary-materials

Abstract: Supplemental Table S7. ROR1 and Ki-67 IHC Expression for Participants With Short and Longer Durations of Treatment

DOI: 10.1158/2767-9764.30146478

Authors: Funda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, Diego Villa, Jun Zhang, Jennifer Friedmann, Fengting Yan, Mark A. Socinski, John Sarantopoulos, Luis E. Raez, Quincy S. Chu, Maxime Chénard-Poirier, Manash S. Chatterjee, Hong Ren, Qi Liu, Douglas A. Levine, Komal L. Jhaveri

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4414292592

Cites:

Cited by:

Related to: 10